Great progress has been made over the past 20 years in elucidating the mechanisms of hepatic fibrogenesis. The recognition of the hepatic stellate cell as the fibrogenic cell of the liver, as well as the recognition of key cytokines involved in fibrogenesis, has facilitated the development of targeted artifibrotic therapies. Patients with chronic hepatitis C and fibrosis may benefit from these novel antifibrotic therapies.

Original languageEnglish
Pages (from-to)94-100
Number of pages7
JournalCurrent Hepatitis Reports
Issue number3
StatePublished - Aug 2006


Dive into the research topics of 'Antifibrotic targets and therapy in HCV'. Together they form a unique fingerprint.

Cite this